Who Pays My Doctor?

Healthcare provider profile · identity verified

Michael G Marcus, MD

Allopathic & Osteopathic Physicians|Pediatrics|Pediatric Pulmonology · BROOKLYN, NY · NPI 1134114192

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show Michael G Marcus, MD received $247,963.04 in general payments during 2025 across 228 reported records.

AstraZeneca Pharmaceuticals LP accounted for 72.5% of that reported general-payment amount.

The Open Payments records used for this analysis explicitly named 5 associated products.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$247,963.04

228 reported records · 4 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported companyCanonical companyAmountShareRecordsYear
AstraZeneca Pharmaceuticals LP Unresolved — no canonical attribution shown $179,766.8672.5%1622025
Regeneron Healthcare Solutions, Inc. Unresolved — no canonical attribution shown $44,709.9318.0%372025
ARS Pharmaceuticals Operations, Inc. Unresolved — no canonical attribution shown $23,460.149.5%282025
Grifols USA, LLC Unresolved — no canonical attribution shown $26.110.0%12025

What were the payments for?

Payment categories

CategoryAmountRecords
Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program$202,275.7870
Travel and Lodging$36,746.5390
Food and Beverage$5,181.7365
Consulting Fee$3,759.003

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Reported productTypeReported companyRelated amount*RecordsYear
FASENRA
Normalized: fasenra		 Biological AstraZeneca Pharmaceuticals LP $91,675.44 76 2025
Source payment records
TEZSPIRE
Normalized: tezspire		 Biological AstraZeneca Pharmaceuticals LP $84,212.13 82 2025
Source payment records
NEFFY
Normalized: neffy		 Drug ARS Pharmaceuticals Operations, Inc. $23,460.14 28 2025
Source payment records
DUPIXENT
Normalized: dupixent		 Biological Regeneron Healthcare Solutions, Inc. $21,133.69 14 2025
Source payment records
Xembify
Normalized: xembify		 Biological Grifols USA, LLC $26.11 1 2025
Source payment records

* Product-associated amounts are non-additive because one payment record may name more than one product.

These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.

Public prescribing for products named in payments

No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

BrandGenericClaimsBeneficiaries
Albuterol Sulfate HfaAlbuterol Sulfate15suppressed
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate15suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

YearGeneral PaymentsMain payerExplicit productsCompany overlapsPart D coverage
2025 $247,963.04 · 228 records AstraZeneca Pharmaceuticals LP DUPIXENT, FASENRA, NEFFY, TEZSPIRE, Xembify — —
2024 — — — — Complete

Questions to ask

Questions you could discuss with your doctor

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Loaded source releases

DatasetYearPublicationSource
CMS Open Payments — General Payments 2025 2026-06-30 Original source
Medicare Part D Prescribers by Provider and Drug 2024 2026-05-06 Original source
NPPES Data Dissemination V2 current / reference data 2026-08-10 Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error